



## TENEBLU TABLETS

*Issue I, No.1, 2025*

### **Teneligliptin as an Adjuvant Therapy in Type 2 Diabetic Management: A Prospective Observational Study**

*Menaka K et.al; Journal of Young Pharmacists, 2024; 16(2):315-321.*

- The goal of this research was designed to prospectively analyze the safety of Teneligliptin, as a supplement therapy in the management of Type 2 DM in south Indian population.
- 302 subjects with diabetes received teneligliptin & the baseline data before initiating the teneligliptin treatment has also been assessed in the study and any changes in each study parameter were analyzed after two and six months of teneligliptin therapy, respectively.
- Efficacy was measured for all the patients after supplemental therapy on teneligliptin and was achieved by calculating Fasting (FPG), Post Prandial (BSPP) for two, four, six months and Glycated Hemoglobin (HbA1c) value at the sixth month from the baseline value.
- A statistically significant FPG, BSPP and HbA1c values compared to that of the baseline value were observed. It is evident that supplemental therapy on teneligliptin at the dose of 20 mg as add-on therapy of teneligliptin with other 3 or 4 oral antidiabetic drugs has been used safely to control the glucose levels.

**This study concluded that teneligliptin achieved good blood glucose control and is well tolerated with no hypoglycemic episodes**

